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Abstract 
Poor induction of mucosal immunity in the intestines by current Salmonella vaccines is a challenge to the 
poultry industry. We prepared and tested an oral deliverable Salmonella subunit vaccine containing 
immunogenic outer membrane proteins (OMPs) and flagellin (F) protein loaded and F-protein surface 
coated chitosan nanoparticles (CS NPs) (OMPs-F-CS NPs). The OMPs-F-CS NPs had mean particle size 
distribution of 514 nm, high positive charge and spherical in shape. In vitro and in vivo studies revealed 
the F-protein surface coated CS NPs were specifically targeted to chicken immune cells. The OMPs-F-CS 
NPs treatment of chicken immune cells upregulated TLRs, and Th1 and Th2 cytokines mRNA expression. 
Oral delivery of OMPs-F-CS NPs in birds enhanced the specific systemic IgG and mucosal IgA antibody 
responses as well as reduced the challenge Salmonella load in the intestines. Thus, user friendly oral 
deliverable chitosan-based Salmonella vaccine for poultry is a viable alternative to current vaccines. 
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Chemical compounds studied in this article 
Chitosan (PubChem CID: 21896651); Sodium tripolyphosphate (PubChem CID: 24455); Acetic 
acid (PubChem CID: 176); Rhodamine B isothiocyanate (PubChem CID: 329753185); 
Potassium thiocyanate (PubChem CID: 516872); Triton X-100 (PubChem CID: 57653560) 
 
Graphical Abstract 
 
Highlights 
 Surface flagellin coated chitosan nanoparticle specifically targets chicken immune cells 
 Chitosan-based Salmonella vaccine treatment increased TLRs, and Th1 and Th2 
cytokines mRNA expression 
 Enhanced immune response and reduced challenge Salmonella load in the intestines of 
vaccinated chickens 
 Chitosan-adjuvanted Salmonella nanovaccine elicits protective response in chickens 
when delivered through drinking water and feed 
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Poor induction of mucosal immunity in the intestines by current Salmonella vaccines is a 
challenge to the poultry industry. We prepared and tested an oral deliverable Salmonella subunit 
vaccine containing immunogenic outer membrane proteins (OMPs) and flagellin (F) protein 
loaded and F-protein surface coated chitosan nanoparticles (CS NPs) (OMPs-F-CS NPs). The 
OMPs-F-CS NPs had mean particle size distribution of 514 nm, high positive charge and 
spherical in shape. In vitro and in vivo studies revealed the F-protein surface coated CS NPs were 
specifically targeted to chicken immune cells. The OMPs-F-CS NPs treatment of chicken 
immune cells upregulated TLRs, and Th1 and Th2 cytokines mRNA expression. Oral delivery of 
OMPs-F-CS NPs in birds enhanced the specific systemic IgG and mucosal IgA antibody 
responses as well as reduced the challenge Salmonella load in the intestines. Thus, user friendly 
oral deliverable chitosan-based Salmonella vaccine for poultry is a viable alternative to current 
vaccines. 
Keywords: Chitosan nanoparticle; Salmonella antigens; TLRs; Oral drinking water and feed 
delivery; Chickens; Immune response 
 
 
 
1. Introduction 
Salmonella is a widely prevalent foodborne pathogen and possesses a high risk of zoonotic 
transmission (Jajere, 2019). Salmonella serovar Enteritidis (S. Enteritidis) is the most common 
serotype causes infection in humans through contact with infected birds and consumption of 
contaminated poultry products (Humphrey & Jorgensen, 2006; Jajere, 2019). Vaccination against 
S. Enteritidis infection in poultry is the most viable strategy to minimize incidences of human 
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Salmonellosis (Greig & Ravel, 2009; Humphrey & Jorgensen, 2006). Commercially available 
Salmonella vaccines are poor inducers of protective mucosal immunity required to control 
enteric infection and colonization of S. Enteritidis. Generally, over 90% of infections caused by 
pathogens are occurring at mucosal surfaces, therefore potent mucosal delivered vaccines which 
induce immune responses at the site of infection are beneficial compared to injectable vaccines 
(Hoft, Brusic, & Sakala, 2011). 
Mucosal vaccination, in particular oral delivery of vaccines is a safe, stress-free and easy to 
administer method that improves economic value of the vaccine (Mestecky, Nguyen, 
Czerkinsky, & Kiyono, 2008). Unlike parenteral immunizations, mucosal vaccination induces 
both systemic and mucosal immune responses (Neutra & Kozlowski, 2006). Salmonella infects 
birds, colonize on intestinal epithelial cells surface and target microfold (M) cells present in 
Peyer’s Patches (PPs) (House, Bishop, Parry, Dougan, & Wain, 2001; Owen & Jones, 1974). 
Oral delivered vaccines should target intestinal M cells of PP’s and reach gut-associated 
lymphoid tissues (GALT) to initiate immune response (Neutra & Kozlowski, 2006). However, 
orally delivered soluble vaccine antigens are degraded by the acidic environment in stomach and 
enzymes present in the gastrointestinal (GI) tract, and/or cleared rapidly by peristaltic movement 
of the intestines resulting in poor sampling by immune cells in the PP’s. Thus, there is a need of 
an innovative vaccine delivery vehicle to overcome those obstacles in the GI tract for oral 
delivered vaccines (Jabbal-Gill, Watts, & Smith, 2012). 
Biocompatible mucoadhesive polymer based nanoparticles are novel candidates for delivering 
vaccine antigens to mucosal immune sites (S. Renu et al., 2018; Renu, Markazi, et al., 2020). 
Mucoadhesive nanoparticles enhance antigen-specific immune responses by reaching the GI tract 
M cells in PP’s (Andrianov & Payne, 1998). Chitosan is a natural mucoadhesive, biodegradable, 
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biocompatible and cationic polymer (Jabbal-Gill et al., 2012). The chitosan nanoparticles (CS 
NPs) are used to deliver proteins, peptides and drugs to mucosa owing to its mucoadhesive 
nature in the intestinal epithelium (van der Lubben, Verhoef, Borchard, & Junginger, 2001). The 
mucoadhesive property of CS NPs is mediated by the electrostatic interactions between the net 
positive charge of CS polymer with negative charge of the intestinal mucosa (Renu, Markazi, et 
al., 2020). The CS NPs has the ability to open up tight junction proteins which facilitate transport 
of particles across the epithelial barrier (Artursson, Lindmark, Davis, & Illum, 1994). Recently, 
we showed biocompatibility of CS NPs in chicken red blood cells, and its stability in different 
acidic and alkaline pH environments (Renu, Markazi, et al., 2020). In our earlier vaccine studies, 
protein antigens encapsulated in CS NPs delivered orally and intranasally induced Th1 and Th2 
cytokines, humoral and cell mediated immune responses in poultry and swine (Dhakal, Renu, et 
al., 2018; Renu, Feliciano-Ruiz, et al., 2020; Renu, Markazi, et al., 2020). The immune adjuvant 
properties of CS NPs include induction of secretion of cytokines (Dhakal, Renu, et al., 2018) and 
activation of antigen presenting cells (APCs) (Choi, Jo, Anower, Islam, & Sohn, 2016; Renu, 
Markazi, et al., 2020). Additionally, CS NPs can be modified to specifically target M cells and 
APCs (Singh et al., 2018). 
Salmonella outer membrane proteins (OMPs) are highly immunogenic and when 
delivered with an adjuvant induces a robust immune response and decrease Salmonella burden in 
birds (S. Renu et al., 2018). The Salmonella surface protein flagellin (F) is also an immunogenic 
agent. It is a toll-like receptor (TLR)-5 agonist and is responsible for bacterial colonization in the 
intestines (Wang et al., 2016). In this study, we optimized CS NPs to deliver Salmonella subunit 
antigens orally to chickens. The optimized formulation of CS NPs containing OMPs and F-
protein loaded and F-protein surface coated (OMPs-F-CS NPs) candidate particulate vaccine 
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when delivered orally through drinking water and feed induced enhanced immune response and 
reduced the challenge bacterial load in layer chickens. 
 
2. Materials and methods 
2.1. Formulation of OMPs-F-CS NPs, empty CS NPs and surface F-protein coated CS NPs 
The CS NPs formulations were prepared using an ionic gelation method as described previously 
(Zhao et al., 2012) with few modification. The 75-85% deacetylated and 50,000-190,000 Da low 
molecular weight chitosan (CS) (Sigma, MO) 1% (W/V) solution was prepared in 1% acetic acid 
under magnetic stirring. The pH of CS solution was adjusted to 4.3, filtered with a 0.44 µm 
syringe filter. The sodium tripolyphosphate (TPP) (Sigma, MO) 1% (W/V) solution was 
prepared in deionized water. For OMPs-F-CS NPs preparation, 5 mL CS solution was poured 
into 45 mL deionized water and incubated with 1 ml PBS pH 7.4 containing 2.5 mg each of both 
OMPs and F-protein under magnetic stirring. Followed by 1.25 mL TPP added to  25 mL 
deionized water was added dropwise using an insulin syringe. After 10 min of incubation, for 
surface coating of particles 1 mg F-protein in 1ml PBS pH 7.4 was added to the formulation, and 
OMPs-F-CS NPs was collected as a pellet after centrifugation at 10,976 ×g for 30 min, dispersed 
in deionized water and used for vaccination. Empty CS NPs and F-protein surface coated CS 
NPs (CS NPs-F) were similarly prepared as mentioned above but without the loaded protein 
antigens. 
For the chicken immune cell uptake study, CS NPs and CS NPs-F were incubated with 1.25 mg 
Rhodamine B isothiocyanate (RITC) (Sigma, MO) for 5 min (Salman, Irache, & Gamazo, 2009) 
and the fluorescent formulations were collected by centrifugation at 10,976 ×g for 30 min and 
dispersed in deionized water. Optimization of CS NPs formulation was performed by using 
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different CS and TPP ratios based on concentration and evaluated based on the particle size and 
zeta potential. 
2.2. Experimental design, vaccination schedule, bacterial challenge and sample collection in 
chickens 
Specific-pathogen-free white Leghorn layer chicks were hatched in-house and raised in 
our BSL2 animal facility. Birds had ad libitum access to water and feed and were housed in 
cages. We followed birds care, sample collection and euthanasia procedures as per the Standards 
of the Institutional Laboratory Animal Care and Use Committee and Ethics for Animal 
Experiments at The Ohio State University (Protocol number: 2016A00000060). At 5 weeks of 
age, chickens were randomly divided into two separate experimental groups and vaccinated 
orally as follows. 
Experiment 1: Thirty chickens (n= 5 per group) were inoculated orally using a gavage 
needle: Groups 1-3, inoculated with 25, 50 and 250 µg each of soluble OMPs and F-protein; 
groups 4-6, the same amount of antigens loaded in OMPs-F-CS NPs (i.e., total of 50, 100 and 
500 µg of OMPs and F-protein in CS NPs). 
Experiment 2: Twenty four chickens were vaccinated as follows: groups 1 and 2, mock 
control received saline orally using a gavage needle (n=5 each); group 3, vaccinated with 250 µg 
each of soluble OMPs and F-protein using an oral gavage needle (n=5); groups 4 and 5, 
vaccinated with OMPs-F-CS NPs encapsulated with a total of 500 µg antigen (250 µg OMPs and 
250 µg FLA) delivered through drinking water (n=5) and feed (n=4). Groups 4 and 5 chickens 
were denied feed and water for 3-4 h before vaccination and allowed to consume the vaccine 
mixed in ~30 mL drinking water or ~200 g feed in their respective groups, respectively. 
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Birds in both the experiments 1 and 2 received first dose of vaccine at 5 weeks of age and 
boosted twice at three weeks apart with the same dose of vaccine at age 8 and 11 weeks. For 
bacterial challenge used the nalidixic acid-resistant virulent S. Enteritidis (Phage type 13a) as  
reported previously (S. Renu et al., 2018). At the age of 14 weeks all chickens, except 
experiment 2 group 1 control birds, were challenged with 5x106 colony-forming unit (CFU) of 
bacteria suspended in 0.5 mL PBS using an oral gavage needle and euthanized 10 days later. 
Samples of saliva and cloacal swabs in 0.5 mL PBS were collected both before and after each 
vaccination. On the day of necropsy blood for serum, bile, ileum, cecum and spleen samples 
were collected, processed and aliquots stored frozen as described previously (S. Renu et al., 
2018). 
2.3. Statistical analyses 
The experimental data were presented as the mean ± standard error of mean (SEM) of 4-5 
chickens per group. In experiment 1, difference between the groups was determined by 
nonparametric Mann-Whitney test (Graphpad Prism version 5, CA). A p< 0.05 was considered 
statistically significant. For experiment 2, differences among the groups were analyzed by 
nonparametric one-way ANOVA followed by Tukey’s post hoc comparison test. If values were 
not statistically significant, then the p value difference between the groups were determined by 
the nonparametric Mann-Whitney test. A p value 0.05 or less was considered statistically 
significant. 
 
3. Results 
3.1. Characterization of CS NPs and OMPs-F-CS NPs 
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In this study, different concentrations CS and TPP expressed in ratios (1:0.5, 3:1, 4:1 and 5:1) 
were used to optimize the CS NPs formulation. The particles size and zeta potential distribution 
of CS NPs were determined using the Zetasizer analyzer (Supplementary Table 1). Based on the 
surface charge and particle size, a 4:1 ratio of CS and TPP was used to formulate CS NPs. The 
CS NPs and OMPs-F-CS NPs were spherical in shape as examined by the field emission Hitachi 
S-4700 scanning electron microscopy (FE-SEM) (Fig. 1A and B), with a mean particle size 
distribution of 224 nm and 514 nm, respectively (Fig. 1C and D), and a similar polydispersity 
index (PDI) of 0.3. CS NPs and OMPs-F-CS NPs had zeta potential distribution of +36 mV and 
+40 mV surface charge, respectively (Fig. 1E and F). The antigens OMPs and F-protein loading 
efficacy in CS NPs was close to 70%. 
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Fig. 1. Characterization of CS NPs and OMPs-F-CS NPs. Field Emission-Scanning Electron 
Microscope analyses of (A) CS NPs and (B) OMPs-F-CS NPs. Mean particle size distribution of 
(C) CS NPs and (D) OMPs-F-CS NPs. Zeta potential distribution of (E) CS NPs and (F) OMPs-
F-CS NPs. 
3.2. In vitro immune cell uptake study of CS NPs-F 
Peripheral blood mononuclear cells (PBMCs) were treated with enriched-RPMI (E-RPMI, 
containing FBS, L-glutamine and antibiotics), F-protein and CS NPs-F for 4 h and 
immunostained for F-protein using specific antibody. Under fluorescence microscopy, CS NPs-C 
B 
Jo
urn
l P
re-
pro
of
11 
 
F-treated PBMCs had high fluorescent green signal, while the control soluble F-protein treated 
cells had weak signal (Fig. 2A). Further to confirm the impact of surface modification of CS NPs 
with F-protein in targeting immune cells, PBMCs were treated with E-RPMI medium, RITC 
fluorescent dye tagged CS NPs and RITC fluorescent dye tagged CS NPs-F. The CS NPs-F-
treated cells had increased bright red fluorescence emission compared to CS NPs treatment (Fig. 
2B). 
 
 
Fig. 2. In vitro PBMCs uptake study of CS NPs-F. (A) Layer chicken PBMCs were treated with 
E-RPMI medium, F-protein and CS NPs-F for 4 h, immunostained using flagellin specific 
antibody and analyzed under an Olympus IX70 fluorescent microscope (4× magnification) in a 
green channel. (B) Layer chicken PBMCs were treated with E-RPMI, RITC dye tagged CS NPs 
and RITC dye tagged CS NPs-F for 4 h and cells were examined in the red channel under the 
Olympus IX70 fluorescent microscope (4× magnification). 
3.3. Oral delivery of CS NPs-F targets the ileum of birds 
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To support our in vitro study results, we orally treated layer chickens with PBS, F- protein, RITC 
dye and RITC dye tagged CS NPs-F. By immunohistochemistry analysis detected  the F-protein 
in PP’s and lamina propria of ileum of only CS NPs-F treated birds, whereas failed to detect any 
such signals in soluble F-protein treated birds tissues (Fig. 3A). In RITC fluorescent dye tagged 
CS NPs-F treated chicken ileum detected red fluorescent emission in the lamina propria whereas 
no such signals were observed in control group birds (Fig. 3B). 
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Fig. 3. In vivo targeting of ileum immune sites by CS NPs-F in layer chickens. (A) Layer 
chickens were orally treated with PBS, F-protein and CS NPs-F for 4 h, ileum was harvested, 
fixed, processed and immunostained with flagellin specific antibody by immunohistochemistry 
and pictures were taken under the Olympus IX70 fluorescent microscope using 20 x objective 
(black arrows - PP’s and Red arrow - Lamina propria). (B) Layer chickens were treated with 
RITC dye and RITC dye-labelled CS NPs-F for 4 h and ileum was harvested, fixed, processed 
and stained with DAPI and visualized under a Life technologies EVOS FL fluorescent 
microscope at 2 x objective. 
3.4. Empty CS NPs and OMPs-F-CS NPs enhanced TLRs, Th1 and Th2 cytokines mRNA 
expression 
To determine the adjuvant properties of CS NPs, the expression of different TLRs, Th1 and Th2 
cytokines mRNA expression in treated chicken immune cells was determined. To optimize the 
assay conditions, PBMCs were treated with OMPs-F-CS NPs and at different time points 12, 24, 
48, and 72 h post treatment analyzed the presence of various TLRs and cytokines gene 
expression. Among all the time points, 24 h post treatment was found optimal for detecting many 
TLRs and 12 h post-treatment for Th1 and Th2 cytokines mRNA expression (data not shown). In 
PBMCs treated for 24 h with OMPs-F-CS NPs observed substantial expression of TLRs 1, 2, 3, 
4, 5, 7, 15 and 21 mRNA compared to soluble OMPs and F-proteins treatment (Fig. 4A-H). 
TLR-1 was significantly (P< 0.01) upregulated in OMP-F-CS NPs-treated cells compared to 
soluble OMPs and F-protein treatment (Fig. 4A). While TLR-2 expression in OMP-F-CS NPs-
treated cells was significantly (P < 0.01 and P < 0.05) higher than both soluble OMPs and F-
protein and empty CS NPs treated cells (Fig. 4B). Interestingly, both TLRs-1 and -2 mRNA 
expressions were downregulated following both empty CS NPs and soluble OMPs and F-protein 
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treatments compared to untreated control cells (Fig. 4A and B). OMPs-F-CS NPs treatment 
significantly (P < 0.05, P < 0.01 and P < 0.001) upregulated TLRs 3, 4, 5, 7, 15 and 21 mRNA 
expressions compared to three control treatments (Fig. 4C-H). Notably, empty CS NPs increased 
the TLRs 3, 4, 5, 7, 15 and 21 mRNA expressions compared to soluble OMPs and F-protein and 
medium control treatments (Fig. 4C-H). 
 
Fig. 4. In vitro TLRs mRNA expression profile in chicken PBMCs treated with OMPs-F-CS 
NPs. PBMCs harvested from three-layer chickens were treated with E-RPMI medium (Control), 
CS NPs, OMPs and F-protein and OMPs-F-CS NPs for 24 h and expression of different TLRs 
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mRNA were analyzed by qRT-PCR. The fold change in mRNA expression levels of (A) TLR-1; 
(B) TLR-2; (C) TLR-3; (D) TLR-4; (E) TLR-5; (F) TLR-7; (G) TLR-15; (H) TLR-21 was 
normalized to the expression of ß-actin. Each bar is the mean ± SEM of 3 chickens and the data 
were analyzed by one-way ANOVA followed by Tukey’s post hoc comparison test. Asterisk 
refers to statistical difference between the indicated treatment groups (*P < 0.05, **P < 0.01 and 
***P < 0.001). 
In PBMCs treated with OMPs-F-CS NPs observed the upregulated expression of both Th1 (IFN-
γ and IL-2) and Th2 (IL-4 and IL-10) cytokines mRNA compared to control treatments (Fig. 5A-
D). Specifically, OMPs-F-CS NPs treatment upregulated 10, 13, 4 and 2-fold higher levels of 
IFN-γ, IL-2, IL-4 and IL-10 mRNA expression, respectively, compared to soluble OMPs and F-
protein treatment (Fig. 5A-D). OMPs-F-CS NPs treatment significantly (P=0.05) upregulated 
IFN-γ mRNA expression in PBMCs compared to empty CS NPs (Fig. 5A). OMPs-F-CS NPs and 
empty CS NPs treatment significantly (P=0.02, P=0.05) upregulated the mRNA expression of 
IL-2 and IL-4 cytokines compared to soluble OMPs and F-protein and untreated control cells 
(Fig. 5B and C). Both OMPs-F-CS NPs and soluble OMPs and F-protein treatment significantly 
(P=0.02) upregulated IL-10 cytokine mRNA expression compared to empty CS NPs and 
untreated control cells (Fig. 5D). 
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Fig. 5. In vitro Th1 and Th2 cytokines mRNA expression profile in chicken PBMCs treated with 
OMPs-F-CS NPs. PBMCs harvested from four-layer chickens were treated with E-RPMI 
medium (Control), CS NPs, OMPs and F-protein and OMPs-F-CS NPs for 12 h and expression 
of Th1 and Th2 cytokines mRNA were analyzed by qRT-PCR. The fold-change in mRNA 
expression levels of (A) IFN-γ; (B) IL-2; (C) IL-4; and (D) IL-10 was normalized to the 
expression of ß-actin. Each bar is the mean ± SEM of four chickens and the data were analyzed 
by one-way ANOVA followed by Tukey’s post hoc comparison test. Asterisk refers to statistical 
difference between the indicated groups (*P < 0.05). If values are not significant the p value 
differences in between the groups were determined by the Mann-Whitney test and marked in the 
graphs. 
3.5. In vivo dose-response of antibodies in OMPs-F-CS NPs inoculated chickens by oral gavage 
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We analyzed the OMPs and F-protein dose-dependent antibody response in chickens received 
OMPs-F-CS NPs delivered by oral gavage. After first dose of vaccine did not observe any 
difference in the specific antibody response compared to soluble OMPs and F-proteins (data not 
shown). However, after second dose vaccination observed increased OMPs-specific IgG and IgA 
antibody response in saliva and cloacal swabs in all three doses of OMPs-F-CS NPs compared to 
soluble proteins group, but the data was statistically significant (P< 0.05) only in cloacal swab 
sample of chickens received 100 µg proteins dose (Fig. 6A-C). 
 
Fig. 6. Oral gavage, drinking water and feed delivered OMPs-F-CS NPs vaccine induced 
antibody responses in layer chickens. Experiment 1: OMPs-specific (A) IgG antibody response 
in Saliva swab; and IgA response in (B) Saliva swab and (C) Cloacal swab were analyzed by 
ELISA. Each bar is the mean ± SEM of 5 chickens and difference between the groups was 
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determined by the Mann-Whitney test. Asterisk refers to statistical difference between the 
indicated groups (*P < 0.05). Experiment 2: OMPs-specific (D) IgG antibody response in Saliva 
swab; and IgA response in (E) Saliva swab and (F) Cloacal swab were analyzed by ELISA. Each 
bar is the mean ± SEM of 4 to 5 chickens. 
3.6. Drinking water and feed-delivered OMPs-F-CS NPs vaccine-induced antigen-specific 
humoral immune response 
Delivery of two doses of OMPs-F-CS NPs vaccine in feed slightly increased OMPs-specific IgG 
antibody response (Fig. 6D), IgA in saliva and cloacal swabs (Fig. 6E and F) compared to 
soluble OMPs and F-protein groups. The OMPs-F-CS NPs vaccine when administered in 
drinking water and feed did not boost the antibody response after third dose of vaccination 
compared to soluble proteins group (data not shown). 
In drinking water delivered OMPs-F-CS NPs-vaccinates after Salmonella challenge infection 
observed enhanced (but not significant) OMPs-specific IgA in bile and cloacal swabs, while IgG 
levels in saliva and serum were comparable to mock challenge group (Fig. 7A-F). But drinking 
water and feed-delivered OMPs-F-CS NPs vaccine significantly (P=0.03 and P=0.01) enhanced 
bile IgG antibody levels compared to soluble OMPs and F-protein group (Fig. 7D). The F-
protein (but not OMPs) specific IgA antibodies in the small intestinal wash were significantly 
(P=0.01) increased in feed delivered OMPs-F-CS NPs vaccinates (Fig. 7G-H). 
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Fig. 7. Salmonella antigen specific antibody responses in layer chickens vaccinated with OMPs-
F-CS NPs through drinking water and feed and then challenged with live S. Enteritidis. OMPs-
specific IgA antibody response in: (A) Bile, (B) Cloacal swab and (C) Saliva; OMPs-specific 
IgG antibody response in (D) Bile, (E) Saliva, and (F) Serum samples; and IgA antibody 
response in small intestinal wash specific to (G) OMPs and (H) F-protein were analyzed by 
ELISA. Each bar is the mean ± SEM of 4 to 5 chickens and the data were analyzed by one-way 
ANOVA followed by Tukey’s post hoc comparison test. If values are not significant the p value 
Jo
urn
l P
re-
pro
of
20 
 
differences in between the groups were determined by the Mann-Whitney test and the actual p 
value is shown in the graphs. 
3.7. Oral delivered OMPs-F-CS NPs vaccine reduced Salmonella shedding 
Both 100 and 500 µg of OMPs and F protein antigens encapsulated OMPs-F-CS NPs vaccine 
delivered by oral gavage significantly (P< 0.01 and P< 0.05) reduced the challenge Salmonella 
load in cecum compared to soluble OMPs and F-protein received birds (Fig. 8A). Drinking water 
delivered OMPs-F-CS NPs significantly (P=0.05) reduced the challenge Salmonella load in 
cecum by around 14 times compared to mock-challenge, and non-significantly (P=0.09) 
compared to soluble OMPs and F-protein vaccinated chickens (Fig. 8B). The feed-delivered 
OMPs-F-CS NPs vaccine reduced Salmonella shedding by 7 times compared to mock-challenge 
and soluble OMPs and F-protein vaccinates (Fig. 8B). Drinking water delivered OMPs-F-CS 
NPs vaccine had marginally better clearance of Salmonella load compared to feed delivered 
vaccine in birds. 
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Fig. 8. Bacterial load in the cecum of OMPs-F-CS NPs inoculated layer chickens. OMPs-F-CS 
NPs vaccine was delivered through (A) Oral gavage and (B) Drinking water and feed followed 
by challenged (Ch) with live S. Enteritidis. Cecum was harvested from both the experimental 
chickens, homogenized, serially 10-fold diluted and plated on XLD agar plates and black color 
S. Enteritidis colonies were counted manually. The results were expressed in log10 CFU. In 
experiment 1, each bar is the mean ± SEM of 5 chickens and difference between the groups was 
determined by the Mann-Whitney test. Asterisk refers to statistical difference between the 
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indicated groups (*P < 0.05, **P < 0.01). In experiment 2, each bar is the mean ± SEM of 4 to 5 
chickens and the data were analyzed by one-way ANOVA followed by Tukey’s post hoc 
comparison test. If values are not significant the p value difference between the groups were 
determined by the Mann-Whitney test and marked in the graphs. 
 
4. Discussion 
Biocompatible and biodegradable polymeric and non-polymeric nanoparticle based mucosal 
vaccine delivery to control infectious and zoonotic diseases of animals appears to surmount 
deficiencies inherent with conventional parenteral vaccine delivery systems (Dhakal, Cheng, et 
al., 2018; Dhakal et al., 2019; Renukaradhya, Narasimhan, & Mallapragada, 2015). Our group 
has reported application of polymer-based nanoparticles for intranasal and oral vaccine delivery 
to combat swine and poultry diseases (Dhakal, Cheng, et al., 2018; Dhakal, Goodman, et al., 
2017; Dhakal, Hiremath, et al., 2017; Dhakal et al., 2019; Dhakal, Renu, et al., 2018; Dwivedi, 
Manickam, Binjawadagi, & Renukaradhya, 2013; Renu, Feliciano-Ruiz, et al., 2020; S. Renu et 
al., 2018; Sankar Renu et al., 2018; Renu, Markazi, et al., 2020). 
Salmonella colonize the small intestine of birds, attaches to mucosal epithelium through flagella 
and are internalized by M cells of PP’s (House et al., 2001; Owen & Jones, 1974). Thus to 
mitigate colonization of Salmonella in intestines and its spread to other tissues developing an 
oral vaccine is ideal (Crump, Luby, & Mintz, 2004). Further, immune responses induced by 
mucosal vaccines are effective and mimic the host response induced by invading mucosal 
pathogens (Jabbal-Gill et al., 2012). The nanoparticle delivery system protects the loaded subunit 
vaccine antigens and facilitates its uptake by endocytosis of nanoparticles by resident dendritic 
cells in the mucosa (Bowman & Leong, 2006; Gao et al., 2016; Xu et al., 2018). In this study, a 
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natural mucoadhesive CS NPs-based Salmonella subunit vaccine candidate deliverable through 
drinking water or feed was developed and tested in poultry. To mimic live Salmonella 
attachment and uptake by M cells in PP’s, the CS NPs surface labeled with F-protein was 
designed and found it localized in orally inoculated small intestine immune sites of chickens. 
The nature of CS NPs makes it ideal for mucosal vaccine delivery. The inter and intra molecular 
linkages of positive charge amino groups of CS with negative charge groups of TPP results in 
spontaneous formation of CS NPs. The vaccine antigen pH was adjusted to be above the 
isoelectric point, thereby facilitating the electrostatic interaction with positively charged CS 
particles (Calvo, Remuñan-López, Vila-Jato, & Alonso, 1997; Renu, Markazi, et al., 2020). 
Formation of the desired size and charge of CS NPs are dependent on the ratio of CS and TPP 
(Seda & Pulat, 2012). In this study, different ratios of CS and TPP were tested and an optimized 
ratio was selected based on the monodispersed smaller particle size distribution and higher 
positive surface charge to prepare OMPs-F-CS NPs vaccine to use in chickens. 
The physicochemical properties including size, charge, shape and encapsulation efficiency are 
the crucial factors for determining optimal biological properties of polymeric nanoparticles (Gao 
et al., 2016). Vibrio anguillarum extracellular product-loaded CS NPs were larger in size with 
higher surface charge compared to empty CS NPs (Gao et al., 2016). The OMPs-F-CS NPs were 
also larger in size and high surface charge compared to empty CS NPs. The PDI value 
determines the size distribution of nanoparticles and a PDI of < 0.5 is considered as 
monodispersed (Gao et al., 2016). The OMPs-F-CS NPs Salmonella vaccine used in this study 
had an average particle size of 514 nm, +40 mV surface charge, 0.3 PDI and spherical in shape. 
Such nanoparticles are likely taken up by clathrin-independent phagocytosis and/or macro-
pinocytosis and induce immune responses (Xiang et al., 2006). A previous study established that 
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200-600 nm nanoparticles are taken up efficiently by APCs, deliver encapsulated antigens and 
induce cell-mediated immune response (Kumar, Anselmo, Banerjee, Zakrewsky, & Mitragotri, 
2015; Oyewumi, Kumar, & Cui, 2010). Positively charged nanoparticles interact with the 
negatively charged cell surfaces promoting its binding and internalization (Josephson, Tung, 
Moore, & Weissleder, 1999). 
Flagellin is a filamentous extracellular protein of Salmonella responsible for locomotion and 
pathogen-host interaction. Flagellin is a virulence factor, TLR-5 agonist, helps in mucoadhesion 
and activates intestinal cells and APCs (Hayashi et al., 2001; Misselwitz et al., 2012). Intranasal 
delivery of F-protein triggers T and B lymphocytes as well as increases the germinal center 
formation in mice (Bates, Honko, Graff, Kock, & Mizel, 2008). Our studies showed that surface 
modified CS NPs with F-protein were better targeted to immune cells and  internalized compared 
to unmodified CS NPs and soluble F-protein. CS NPs alone have immunomodulation function in 
APCs, natural killer cells and T cells, and oral inoculation of CS NPs stimulates PBMCs and 
lymph nodes cells in mice (Choi et al., 2016). The F-protein modified mucoadhesive 
nanoparticles delivered orally in rat and poultry mimic Salmonella-like gut colonization and 
targets to M cells PP’s (S. Renu et al., 2018; Salman, Gamazo, Campanero, & Irache, 2005). 
Modified CS NPs are highly resistant to enzymatic and acid degradation and targets intestinal 
PP’s of rats (Xu et al., 2018). Similarly, in this study when CS NPs-F delivered orally in chicken 
reached the ileum and detected in PP’s and lamina propria. Antigen-loaded CS NPs are taken up 
and processed by M cells in vitro (Slutter et al., 2009). 
The TLRs are germline-encoded pathogen recognition receptors highly expressed in APCs 
(Kawai & Akira, 2009). TLRs detect a wide range of pathogen-associated molecular patterns 
from microbes, and thereby offer rapid innate protection to pathogens (Bianchi, 2007; 
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Geijtenbeek & Gringhuis, 2009). In this study, OMPs-F-CS NPs treatment triggered the 
expression of both cell surface and endosomal TLRs, as well as enhanced Th1 and Th2 cytokines 
mRNA expression in chicken immune cells. TLRs ligands activate immature dendritic cells to 
mature in lymph nodes, process antigen to naïve T cells and stimulate immune response. 
Inactivated and subunit vaccines often require TLR adjuvants to augment adaptive immunity 
(Coffman, Sher, & Seder, 2010). The TLRs induce secretion of inflammatory cytokines and 
adhesion and expression of co-stimulatory molecules on APCs essential for adaptive immunity 
(Pasare & Medzhitov, 2005). In mice, antigen-loaded CS NPs immunization resulted in 
upregulated expression of Th1 (IL-2 and IFN-γ) and Th2 (IL-10) cytokines mRNA in 
splenocytes (Wen, Xu, Zou, & Xu, 2011). In our recent studies, influenza antigen encapsulated 
CS NPs treated pig dendritic cells culture supernatant detected increased innate, pro-
inflammatory and Th1 cytokines (Dhakal, Renu, et al., 2018). Orally delivered chitosan-
Salmonella subunit nanoparticle vaccine upregulated TLR-2, TLR-4, IFN-γ, TGF-ß and IL-4 
mRNA expression in chicken cecal tonsils (Renu, Markazi, et al., 2020). A study revealed that 
CS NPs helps in maturation of dendritic cells and upregulated the antigen specific Th1 response 
(Carroll et al., 2016). 
Approximately 70-80% of secretory antibody producing B cells in the body reside in the small 
intestine and are responsible for eliciting immunity in the intestines as a first line of defense 
against colonizing pathogens (Brandtzaeg, 1989). Adjuvant-based vaccines, delivered orally, 
induce both local and systemic immunity (Azizi, Kumar, Diaz-Mitoma, & Mestecky, 2010). We 
found that Salmonella antigen-loaded mucoadhesive polyanhydride nanoparticle delivered by 
oral gavage in layer chickens enhanced antibody response to Salmonella antigens (S. Renu et al., 
2018). In this study, both 50 and 100 µg dose of Salmonella antigens in OMPs-F-CS NPs 
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vaccine delivered by oral gavage induced an immune response comparable to the 500 µg dose of 
vaccine given through drinking water or feed. This include increased secretion of antigen 
specific systemic, secretory and mucosal antibody responses compared to soluble OMPs and F-
protein group. In an earlier study, around 500 nm size nanoparticle delivered vaccine antigens 
were taken up by immune cells and promoted humoral immune response (Xiang et al., 2006). 
Our results using CS NPs are consistent with oral vaccination-induced enhanced antibody 
response by nanoparticle vaccine delivery platforms (Biswas, Chattopadhyay, Sen, & Saha, 
2015; Dubey et al., 2016; Renu, Markazi, et al., 2020; Xu et al., 2018; Zhao et al., 2012). 
Edwardsiella tarda OMPs encapsulated CS NPs when inoculated orally significantly increases 
antibody levels in Labeo fimbriatus fish and provides protection against the disease (Dubey et 
al., 2016). Oral delivery of measles antigen-loaded CS NPs, but not subcutaneous administration, 
enhanced intestinal IgA antibody titer in mice (Biswas et al., 2015). Oral inoculation of 
Helicobacter pylori therapeutic vaccine in CS NPs compared to cholera toxin adjuvant induced 
greater antibody and Th1/Th2 immune responses resulting in better clearance of the bacteria 
(Gong et al., 2015). Lentogenic live-virus encapsulated in CS NPs delivered orally in chicken 
increases intestinal IgA antibody levels and completely protects chickens from Newcastle 
disease virus infection (Zhao et al., 2012). Orally delivered chitosan-Salmonella subunit 
nanoparticle vaccine enhanced antigen specific secretory IgA antibody response both in 
vaccinated and Salmonella challenged layer chickens (Renu, Markazi, et al., 2020). 
In this study, oral gavage, drinking water and feed-delivered OMPs-F-CS NPs vaccine reduced 
the challenge Salmonella load in layer chickens compared to soluble proteins, suggesting that 
reduced bacterial load in OMPs-F-CS NPs vaccinates was mediated by the adjuvant effect as 
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well as efficient vaccine delivery to mucosal immune cells, irrespective of the mode of vaccine 
given orally in chickens. 
5. Conclusions 
We formulated a mucoadhesive oral drinking water and feed deliverable OMPs-F-CS NPs 
vaccine. The F-protein surface modified CS NPs targets chicken immune cells. CS NPs-
adjuvanted Salmonella vaccine increased the expression of different TLRs and Th1 and Th2 
cytokines mRNA expression in chicken immune cells. Delivery of OMPs-F-CS NPs vaccine 
through drinking water and feed enhanced antigen-specific antibody response and reduced the 
challenge Salmonella load in layer chickens. This study demonstrates that Salmonella subunit 
antigens can be delivered efficiently using CS NPs by the oral route. Further studies are aimed at 
comparing the OMPs-F-CS NPs vaccine efficacy with the commercial live and killed Salmonella 
vaccines. 
 
Credit Author Statement 
SR: Conceptualization; Data curation; Formal analysis; Methodology; Roles/Writing - original 
draft; Writing - review & editing. 
YH: Data curation; Methodology. 
SD: Data curation 
YSL: Data curation 
SG: Data curation 
NFR: Data curation 
Jo
urn
al 
Pre
-pr
of
28 
 
SS: Data curation 
BN: Funding acquisition; Investigation 
RS: Formal analysis; Funding acquisition; Investigation 
GJR: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; 
Methodology; Project administration; Resources; Supervision; Validation; Writing - review & 
editing. 
 
Disclosures 
The authors have no financial conflict of interest. 
 
Acknowledgments 
We thank Dr. Juliette Hanson, Megan Strother and Sara Tallmadge for their help in 
animal studies. We are thankful to Dr. Tea Meulia and Horst Leona, MCIC, OARDC for their 
assistance in FE-SEM analyses. We thank Dr. Steven Krakowka for scientific editing of the 
manuscript. Current research was supported by OSU Accelerator award. Salaries and research 
support were provided by the state and federal funds appropriated to OARDC, The Ohio State 
University. 
  Jo
urn
al 
Pre
-pr
oo
f
29 
 
References 
Andrianov, A. K., & Payne, L. G. (1998). Polymeric carriers for oral uptake of microparticulates. 
Adv Drug Deliv Rev, 34(2-3), 155-170. 
Artursson, P., Lindmark, T., Davis, S. S., & Illum, L. (1994). Effect of chitosan on the 
permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res, 11(9), 
1358-1361. 
Azizi, A., Kumar, A., Diaz-Mitoma, F., & Mestecky, J. (2010). Enhancing oral vaccine potency 
by targeting intestinal M cells. PLoS Pathog, 6(11), e1001147. 
Bates, J. T., Honko, A. N., Graff, A. H., Kock, N. D., & Mizel, S. B. (2008). Mucosal adjuvant 
activity of flagellin in aged mice. Mech Ageing Dev, 129(5), 271-281. 
Bianchi, M. E. (2007). DAMPs, PAMPs and alarmins: all we need to know about danger. J 
Leukoc Biol, 81(1), 1-5. 
Biswas, S., Chattopadhyay, M., Sen, K. K., & Saha, M. K. (2015). Development and 
characterization of alginate coated low molecular weight chitosan nanoparticles as new 
carriers for oral vaccine delivery in mice. Carbohydr Polym, 121, 403-410. 
Bowman, K., & Leong, K. W. (2006). Chitosan nanoparticles for oral drug and gene delivery. Int 
J Nanomedicine, 1(2), 117-128. 
Brandtzaeg, P. (1989). Overview of the mucosal immune system. Curr Top Microbiol Immunol, 
146, 13-25. 
Calvo, P., Remuñan-López, C., Vila-Jato, J. L., & Alonso, M. J. (1997). Chitosan and 
Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel 
Carriers for Proteins and Vaccines. Pharmaceutical Research, 14(10), 1431-1436. 
Carroll, E. C., Jin, L., Mori, A., Munoz-Wolf, N., Oleszycka, E., Moran, H. B. T., . . . Lavelle, E. 
C. (2016). The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor 
cGAS-STING-Dependent Induction of Type I Interferons. Immunity, 44(3), 597-608. 
Choi, B., Jo, D. H., Anower, A. K., Islam, S. M., & Sohn, S. (2016). Chitosan as an 
Immunomodulating Adjuvant on T-Cells and Antigen-Presenting Cells in Herpes 
Simplex Virus Type 1 Infection. Mediators Inflamm, 2016, 4374375. 
Coffman, R. L., Sher, A., & Seder, R. A. (2010). Vaccine adjuvants: putting innate immunity to 
work. Immunity, 33(4), 492-503. 
Crump, J. A., Luby, S. P., & Mintz, E. D. (2004). The global burden of typhoid fever. Bull World 
Health Organ, 82(5), 346-353. 
Dhakal, S., Cheng, X., Salcido, J., Renu, S., Bondra, K., Lakshmanappa, Y. S., . . . 
Renukaradhya, G. J. (2018). Liposomal nanoparticle-based conserved peptide influenza 
vaccine and monosodium urate crystal adjuvant elicit protective immune response in 
pigs. Int J Nanomedicine, 13, 6699-6715. 
Dhakal, S., Goodman, J., Bondra, K., Lakshmanappa, Y. S., Hiremath, J., Shyu, D. L., . . . 
Renukaradhya, G. J. (2017). Polyanhydride nanovaccine against swine influenza virus in 
pigs. Vaccine, 35(8), 1124-1131. 
Dhakal, S., Hiremath, J., Bondra, K., Lakshmanappa, Y. S., Shyu, D. L., Ouyang, K., . . . 
Renukaradhya, G. J. (2017). Biodegradable nanoparticle delivery of inactivated swine 
influenza virus vaccine provides heterologous cell-mediated immune response in pigs. J 
Control Release, 247, 194-205. 
Jo
urn
al 
Pre
-pr
oo
f
30 
 
Dhakal, S., Lu, F., Ghimire, S., Renu, S., Lakshmanappa, Y. S., Hogshead, B. T., . . . 
Renukaradhya, G. J. (2019). Corn-derived alpha-D-glucan nanoparticles as adjuvant for 
intramuscular and intranasal immunization in pigs. Nanomedicine, 16, 226-235. 
Dhakal, S., Renu, S., Ghimire, S., Shaan Lakshmanappa, Y., Hogshead, B. T., Feliciano-Ruiz, 
N., . . . Renukaradhya, G. J. (2018). Mucosal Immunity and Protective Efficacy of 
Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery 
in Pigs. Front Immunol, 9, 934. 
Dubey, S., Avadhani, K., Mutalik, S., Sivadasan, S. M., Maiti, B., Girisha, S. K., . . . 
Munang'andu, H. M. (2016). Edwardsiella tarda OmpA Encapsulated in Chitosan 
Nanoparticles Shows Superior Protection over Inactivated Whole Cell Vaccine in Orally 
Vaccinated Fringed-Lipped Peninsula Carp (Labeo fimbriatus). Vaccines (Basel), 4(4). 
Dwivedi, V., Manickam, C., Binjawadagi, B., & Renukaradhya, G. J. (2013). PLGA nanoparticle 
entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in 
viral clearance in pigs. Vet Microbiol, 166(1-2), 47-58. 
Gao, P., Xia, G., Bao, Z., Feng, C., Cheng, X., Kong, M., . . . Chen, X. (2016). Chitosan based 
nanoparticles as protein carriers for efficient oral antigen delivery. Int J Biol Macromol, 
91, 716-723. 
Geijtenbeek, T. B., & Gringhuis, S. I. (2009). Signalling through C-type lectin receptors: shaping 
immune responses. Nat Rev Immunol, 9(7), 465-479. 
Gong, Y., Tao, L., Wang, F., Liu, W., Jing, L., Liu, D., . . . Zhou, N. (2015). Chitosan as an 
adjuvant for a Helicobacter pylori therapeutic vaccine. Mol Med Rep, 12(3), 4123-4132. 
Greig, J. D., & Ravel, A. (2009). Analysis of foodborne outbreak data reported internationally 
for source attribution. Int J Food Microbiol, 130(2), 77-87. 
Hayashi, F., Smith, K. D., Ozinsky, A., Hawn, T. R., Yi, E. C., Goodlett, D. R., . . . Aderem, A. 
(2001). The innate immune response to bacterial flagellin is mediated by Toll-like 
receptor 5. Nature, 410(6832), 1099-1103. 
Hoft, D. F., Brusic, V., & Sakala, I. G. (2011). Optimizing vaccine development. Cell Microbiol, 
13(7), 934-942. 
House, D., Bishop, A., Parry, C., Dougan, G., & Wain, J. (2001). Typhoid fever: pathogenesis 
and disease. Curr Opin Infect Dis, 14(5), 573-578. 
Humphrey, T., & Jorgensen, F. (2006). Pathogens on meat and infection in animals - 
Establishing a relationship using campylobacter and salmonella as examples. Meat Sci, 
74(1), 89-97. 
Jabbal-Gill, I., Watts, P., & Smith, A. (2012). Chitosan-based delivery systems for mucosal 
vaccines. Expert Opin Drug Deliv, 9(9), 1051-1067. 
Jajere, S. M. (2019). A review of Salmonella enterica with particular focus on the pathogenicity 
and virulence factors, host specificity and antimicrobial resistance including multidrug 
resistance. Vet World, 12(4), 504-521. 
Josephson, L., Tung, C. H., Moore, A., & Weissleder, R. (1999). High-efficiency intracellular 
magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug 
Chem, 10(2), 186-191. 
Kawai, T., & Akira, S. (2009). The roles of TLRs, RLRs and NLRs in pathogen recognition. Int 
Immunol, 21(4), 317-337. 
Kumar, S., Anselmo, A. C., Banerjee, A., Zakrewsky, M., & Mitragotri, S. (2015). Shape and 
size-dependent immune response to antigen-carrying nanoparticles. J Control Release, 
220(Pt A), 141-148. 
Jo
urn
al
Pre
-pr
o
f
31 
 
Mestecky, J., Nguyen, H., Czerkinsky, C., & Kiyono, H. (2008). Oral immunization: an update. 
Curr Opin Gastroenterol, 24(6), 713-719. 
Misselwitz, B., Barrett, N., Kreibich, S., Vonaesch, P., Andritschke, D., Rout, S., . . . Hardt, W. 
D. (2012). Near surface swimming of Salmonella Typhimurium explains target-site 
selection and cooperative invasion. PLoS Pathog, 8(7), e1002810. 
Neutra, M. R., & Kozlowski, P. A. (2006). Mucosal vaccines: the promise and the challenge. Nat 
Rev Immunol, 6(2), 148-158. 
Owen, R. L., & Jones, A. L. (1974). Epithelial cell specialization within human Peyer's patches: 
an ultrastructural study of intestinal lymphoid follicles. Gastroenterology, 66(2), 189-
203. 
Oyewumi, M. O., Kumar, A., & Cui, Z. (2010). Nano-microparticles as immune adjuvants: 
correlating particle sizes and the resultant immune responses. Expert Rev Vaccines, 9(9), 
1095-1107. 
Pasare, C., & Medzhitov, R. (2005). Toll-like receptors: linking innate and adaptive immunity. 
Adv Exp Med Biol, 560, 11-18. 
Renu, S., Feliciano-Ruiz, N., Ghimire, S., Han, Y., Schrock, J., Dhakal, S., . . . Renukaradhya, G. 
J. (2020). Poly(I:C) augments inactivated influenza virus-chitosan nanovaccine induced 
cell mediated immune response in pigs vaccinated intranasally. Vet Microbiol, 242, 
108611. 
Renu, S., Markazi, A. D., Dhakal, S., Lakshmanappa, Y. S., Gourapura, S. R., 
Shanmugasundaram, R., . . . Renukaradhya, G. J. (2018). Surface engineered 
polyanhydride-based oral Salmonella subunit nanovaccine for poultry. Int J 
Nanomedicine, 13, 8195-8215. 
Renu, S., Markazi, A. D., Dhakal, S., Lakshmanappa, Y. S., Shanmugasundaram, R., Selvaraj, R. 
K., & Renukaradhya, G. J. (2018). Engineering of Targeted Mucoadhesive Chitosan 
Based Salmonella Nanovaccine for Oral Delivery in Poultry. The Journal of Immunology, 
200(1 Supplement), 118.115-118.115. 
Renu, S., Markazi, A. D., Dhakal, S., Lakshmanappa, Y. S., Shanmugasundaram, R., Selvaraj, R. 
K., & Renukaradhya, G. J. (2020). Oral Deliverable Mucoadhesive Chitosan-Salmonella 
Subunit Nanovaccine for Layer Chickens. Int J Nanomedicine, 15, 761-777. 
Renukaradhya, G. J., Narasimhan, B., & Mallapragada, S. K. (2015). Respiratory nanoparticle-
based vaccines and challenges associated with animal models and translation. J Control 
Release, 219, 622-631. 
Salman, H. H., Gamazo, C., Campanero, M. A., & Irache, J. M. (2005). Salmonella-like 
bioadhesive nanoparticles. J Control Release, 106(1-2), 1-13. 
Salman, H. H., Irache, J. M., & Gamazo, C. (2009). Immunoadjuvant capacity of flagellin and 
mannosamine-coated poly(anhydride) nanoparticles in oral vaccination. Vaccine, 27(35), 
4784-4790. 
Seda, T. A., & Pulat, M. (2012). 5-Fluorouracil Encapsulated Chitosan Nanoparticles for pH-
Stimulated Drug Delivery: Evaluation of Controlled Release Kinetics. Journal of 
Nanomaterials, 2012, 10. 
Singh, B., Maharjan, S., Cho, K. H., Cui, L., Park, I. K., Choi, Y. J., & Cho, C. S. (2018). 
Chitosan-based particulate systems for the delivery of mucosal vaccines against 
infectious diseases. Int J Biol Macromol, 110, 54-64. 
Jo
u n
l P
re-
pr
of
32 
 
Slutter, B., Plapied, L., Fievez, V., Sande, M. A., des Rieux, A., Schneider, Y. J., . . . Preat, V. 
(2009). Mechanistic study of the adjuvant effect of biodegradable nanoparticles in 
mucosal vaccination. J Control Release, 138(2), 113-121. 
van der Lubben, I. M., Verhoef, J. C., Borchard, G., & Junginger, H. E. (2001). Chitosan for 
mucosal vaccination. Adv Drug Deliv Rev, 52(2), 139-144. 
Wang, G., Shi, B., Li, T., Zuo, T., Wang, B., Si, W., . . . Liu, H. (2016). Linear antigenic 
mapping of flagellin (FliC) from Salmonella enterica serovar Enteritidis with yeast 
surface expression system. Vet Microbiol, 184, 20-26. 
Wen, Z. S., Xu, Y. L., Zou, X. T., & Xu, Z. R. (2011). Chitosan nanoparticles act as an adjuvant 
to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar 
Drugs, 9(6), 1038-1055. 
Xiang, S. D., Scholzen, A., Minigo, G., David, C., Apostolopoulos, V., Mottram, P. L., & 
Plebanski, M. (2006). Pathogen recognition and development of particulate vaccines: 
does size matter? Methods, 40(1), 1-9. 
Xu, B., Zhang, W., Chen, Y., Xu, Y., Wang, B., & Zong, L. (2018). Eudragit(R) L100-coated 
mannosylated chitosan nanoparticles for oral protein vaccine delivery. Int J Biol 
Macromol, 113, 534-542. 
Zhao, K., Chen, G., Shi, X. M., Gao, T. T., Li, W., Zhao, Y., . . . Wang, Y. F. (2012). Preparation 
and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan 
nanoparticles. PLoS One, 7(12), e53314. 
 
Jo
urn
al 
Pre
-pr
oo
f
